Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02532114 · ClinicalTrials.gov registry record · Phase 1
Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer
A Phase 1 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT02532114 is a Phase 1 study that has completed, run by University of Washington. The registered enrollment target is 5 participants.
The verdict
NCT02532114, a Phase 1 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of niclosamide when given together with enzalutamide in treating patients with castration resistant prostate cancer that has spread from the primary site to other places in the body. Androgens such as testosterone can cause the growth of prostate cancer cells. Drugs like enzalutamide block androgens from driving tumor growth; however, when androgen receptor splice variants are present, these drugs may not be effective. Niclosamide may decrease the amount of androgen receptor splice variant present within tumor cells, thus promoting the anti-tumor effects of enzalutamide. Giving niclosamide together with enzalutamide may be a better treatment for prostate cancer.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Enzalutamide
- DRUG Niclosamide
- OTHER Pharmacological Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2015-12-31 |
| Est. Completion | 2017-11-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02532114
The ClinicalTrials.gov registry entry for NCT02532114 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02532114 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02532114 about?
NCT02532114 is a clinical study titled "Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer". This phase I trial studies the side effects and best dose of niclosamide when given together with enzalutamide in treating patients with castration resistant prostate cancer that has spread from the primary site to other places in the body. Androgens such as testosterone can cause the growth of pros...
What is the current status of trial NCT02532114?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2015-12-31. Estimated completion is 2017-11-30.
What interventions are being tested in trial NCT02532114?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Enzalutamide (DRUG), Niclosamide (DRUG), Pharmacological Study (OTHER).
Who is sponsoring clinical trial NCT02532114?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.